ORIENT BIO Inc. (KRX:002630)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,855.00
+280.00 (17.78%)
At close: Mar 27, 2025, 3:30 PM KST

ORIENT BIO Revenue

ORIENT BIO had revenue of 17.21B KRW in the quarter ending December 31, 2021, with 21.77% growth. This brings the company's revenue in the last twelve months to 59.09B, up 19.53% year-over-year. In the fiscal year ending March 31, 2021, ORIENT BIO had annual revenue of 52.02B with 39.79% growth.

Revenue (ttm)
59.09B
Revenue Growth
+19.53%
P/S Ratio
3.34
Revenue / Employee
472.73M
Employees
125
Market Cap
197.42B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 202152.02B14.81B39.79%
Mar 31, 202037.21B6.84B22.52%
Mar 31, 201930.37B4.75B18.53%
Mar 31, 201825.62B-83.39B-76.50%
Mar 31, 2017109.02B3.97B3.78%
Mar 31, 2016 Pro Pro Pro
Mar 31, 2015 Pro Pro Pro
Mar 31, 2014 Pro Pro Pro
Mar 31, 2013 Pro Pro Pro
Mar 31, 2012 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,547.32B
Celltrion 3,557.30B
ALTEOGEN 102.85B
Yuhan 2,067.79B
SK Biopharmaceuticals 547.60B
HLB Co., Ltd. 51.92B
Sam Chun Dang Pharm. 210.92B
PharmaResearch 350.12B
Revenue Rankings